Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03931551
Title Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer (OPHELIA)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedSIR
Indications

Her2-receptor positive breast cancer

Therapies

Olaparib + Trastuzumab

Age Groups: senior | adult
Covered Countries ESP


No variant requirements are available.